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Metabolic chiral inversion of 
2-arylpropionic acid derivatives (profens)
ABSTRACT
2-arylpropionic acid derivatives (profens) are one of the most popular anti-inflammatory, analgesic, and 
antipyretic drugs. They belong to a group of nonsteroidal anti-inflammatory drugs (NSAID) and exhibit 
metabolic chiral inversion. Enantiomers of these chiral drugs are often characterised by different pharma-
cological activity. It is estimated that the values of metabolic chiral inversion of (R)-ibuprofen in humans 
are between 35 and 70%, depending on the condition of the liver and the intake of other medicines, 
while (R)-flurbiprofen undergoes chiral metabolic inversion to its opposed (S) form only in small range. 
The described phenomenon in the case of (R)-ketoprofen is limited to a maximum of around 10%. The 
metabolic chiral inversion is associated with potentially important pharmacotherapeutic and toxicological 
consequences, and so an attempt was made to analyse this phenomenon for the most commonly used 
drugs from the profens group.
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Introduction
Currently, according to data of the American Food 
and Drug Administration (FDA), optically pure com-
pounds represent more than a half of the total investi-
gational new drugs (INDs).
This quantity of tested drugs is reflected in the com-
mercial availability of enantiomers. Eighty percent of the 
best-selling drugs in the United States are enantiomers 
of chiral compounds [1].
2-arylpropionic acid derivatives (profens) belong to 
nonsteroidal anti-inflammatory drugs (NSAID) and have 
a chiral centre (chiral carbon atom) within the propionic 
acid moiety, and therefore exist in two enantiomeric 
forms: (R)-enantiomer and (S)-enantiomer. Clinically 
used racemic mixture (racemate) consists of an equi-
molar mixture of two enantiomers ((R) and (S)). Profens 
are widely administered in the inflammatory conditions, 
to relieve pain and to reduce fever [2, 3]. Due to pres-
ence of the profen forms (R) and (S), a phenomenon 
called metabolic chiral inversion of these drugs can be 
observed in the human body. It occurs in the presence 
of enzymes that determine the change in enantiomeric 
composition of chiral drug and/or metabolites by inver-
sion of one form to its antipode [4].
The aim of this mini-review is to demonstrate the 
phenomenon called metabolic chiral inversion of 2-aryl- 
propionic acid derivatives (profens) and to indicate 
pharmacotherapeutic and toxicological consequences 
of profens administration in racemic form.
Metabolic chiral inversion of profens
It has been shown that (R)-enantiomers of profens in 
the presence of coenzyme A (CoA), adenosine triphos-
phate (ATP) and Mg2+ are transformed to active (S)-forms 
(Fig. 1). The pathway consists of three parts, beginning 
from the synthesis of (R)-profen thioester with the use 
of coenzyme A; racemisation of (R)-profen thioester 
and hydrolysis. The first step occurs when formation 
of thioester from (R)-profen and coenzyme A is started. 
This reaction is catalysed by acyl-CoA synthetase. The 
next step is racemisation (epimerisation) of the obtained 
(R)-thioester by the activity of epimerase 2-arylpropion-
ic-CoA. Afterwards, newly created thioesters hydrolyse 
to (R)- and (S)-forms, with the use of hydrolase. The 
metabolic chiral inversion may lead to toxic effects, due to 
modulation of triglicerydes and phospholipids structures 
by the acyl-CoA thioester (profenyl-CoA) [4, 5].
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Figure 1. Mechanism of metabolic chiral inversion of 
profens [4]
Figure 2. Molecular structures of (S)- and (R)-ibuprofen
(R,S)-ibuprofen
Ibuprofen (2-[4-(isobutyl)phenyl]propionic acid) is 
a substance that belongs to nonsteroidal anti-inflamma-
tory drug (NSAID) 2-arylopropionic acid derivatives. Due 
to the presence of the chiral a atom of carbon in its 
structure, it is defined as an optically active compound. 
Ibuprofen exists as a racemic mixture of two enantio-
mers: (R) and (S), which are characterised by different 
pharmacokinetic and pharmacodynamic profiles 
(Fig. 2) [6]. It has been proven in in vitro tests that (S) 
isomer shows about 160-times higher activity in prosta-
glandins inhibition compared to (R) enantiomer. (S)-en-
antiomer equally inhibits the activity of COX-1 and COX-
2, while (R)-ibuprofen inhibits COX-1 less potently than 
(S)-form and demonstrates no inhibition of COX-2. It 
should be emphasised that (R)-ibuprofen increases the 
side effects caused by the intake of racemic mixture, 
mainly from the gastrointestinal tract [4].
Created thioesters from coenzyme A and ibuprofen 
can incorporate into triglycerides or phospholipids 
forming ‘hybrids’. In adipose tissue, the estimated 
elimination half-life (t1/2) of the ‘hybrids’ is about seven 
days. The data show that only (R)-enantiomer was 
detected in human adipose tissue, when both (S)- and 
(R)-enantiomers were used in experiment. No accumu-
lation of (S)-ibuprofen was noticed. Actually, studies on 
the effect of ‘hybrids’ in the adipose tissue and their long 
t1/2 have been performed. It has been demonstrated that 
creation of ‘hybrids’ with phospholipids may have an 
influence on the function of the cell membranes. It is 
estimated that the values of metabolic chiral inversion 
of (R)-ibuprofen in humans are between 35 and 70%, 
depending on the condition of the liver and the intake 
of medicines [5, 7].
It was proven that oral administration of pure (S)-ibu-
profen allows a stronger analgesic effect in a shorter 
time, compared with racemic mixture that contained 
approximately the same amount of active (S)-form. 
Moreover, the research conducted on 1400 patients 
showed higher effectiveness of therapy and signifi-
cantly reduced side effects, while only (S)-ibuprofen 
was used [8, 9]. Commercially available formulations 
of this medicine are racemic mixtures (Ibuprofen) or 
single (S)-enantiomer (Dexibuprofen).
(R,S)-flurbiprofen
Another one of the broadly applicable nonsteroidal 
anti-inflammatory drugs of 2-arylpropionic acid deriva-
tives is (R,S)-flurbiprofen [2-(2-fluoro-4-biphenyl)-pro-
pionic acid]. This drug possesses a chiral centre and 
therefore exists in two enantiomeric forms: (R)- and 
(S)-flurbiprofen, which demonstrate various pharma-
cokinetic and pharmacodynamic activities (Fig. 3). 
Nevertheless, clinically (R,S)-flurbiprofen is used as 
a racemic mixture, not as an individual enantiomer 
[10–12]. (S)-enantiomer exhibits an inhibitory effect 
on cyclooxygenase (COX-2), thus anti-inflammatory 
action is determined. This enantiomer also shows ac-
tivity towards cyclooxy genase-1 and thereby induces 
gastrointestinal side effects. Analysing the influence of 
(R)-form, it has been reported that this enantiomer has 
no effect on cyclooxygenase (alike COX-1 and COX-2) 
and is therefore less toxic to the kidneys and gastroin-
testinal tract, and what is important, in vivo in a small 
range it undergoes chiral metabolic inversion to its 
opposed form (S) [13, 14]. Currently, the mechanism of 
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Figure 3. Molecular structures of (S)- and (R)-flurbiprofen
Figure 4. Molecular structures of (S)- and (R)-ketoprofen
molecular action of (R)-flurbiprofen is being investigated 
and it seems to be not related with COX inhibition. It 
has been proven in cell lines and animal models that 
(R)-enantiomer might be useful in oncology in treatment 
of colon and prostate cancers [15–19].
(R,S)-ketoprofen
The next representative of 2-arylpropionic acids 
derivatives is ketoprofen (2-(3-benzoylphenyl)-pro-
pionic acid) [20, 21]. The pharmacological actions 
of ketoprofen are similar to other NSAIDs, so the 
anti-inflammatory and analgesic effects are observed 
due to the inhibition of cyclooxygenase-2 (COX-2). 
The drug also expresses COX-1 inhibiting activity, 
and this is the reason why it enhances the risk of 
gastrointestinal side effects while repeatedly taken 
orally [22]. The particle is also a chiral compound 
since it possesses a centre of asymmetry. Ketoprofen, 
analogically as all 2-arylpropionic acid derivatives, 
exists in two forms: (S)- and (R)-enantiomer (Fig. 4). 
What is important, only (S)-enantiomer of ketoprofen 
possesses the pharmacological activity, while (R)-en-
antiomer is either completely inactive or possesses 
low activity [23, 24]. 
It was confirmed that the chiral metabolic inversion 
of (R) to (S)-ketoprofen is limited to around 10% [25]. 
Other authors claim that no relevant enantiomeric inver-
sion of (R)- to (S)-form has been registered [4, 26, 27]. 
Commercially available formulations of this drug are 
racemic mixtures (ketoprofen) or single (S)-enantiomer 
(dexketoprofen).
(S)-naproxen
The last described drug from 2-arylpropionic acid 
derivatives is naproxen (2-[6-methoxy-2-naphthyl]-pro-
pionic acid) (Fig. 5). Due to the well documented hep-
atotoxicity and the effect of increasing the burden on 
renal clearance of (R)-naproxen, it is the only NSAID 
that is administrated as a stereochemically pure (S)-en-
antiomer. Similarly to other NSAIDs, naproxen is used 
as a treatment of arthritis, febrile syndrome, and pain 
because of its analgesic, antipyretic, and anti-inflamma-
tory activity. Naproxen is a nonselective COX inhibitor 
with a balanced inhibitory effect on both COX-isozymes 
(COX-1 and COX-2) [28–30]. This drug possesses also 
a chiral centre, and it was observed in in vitro tests 
concerning inhibition of prostaglandin synthesis that 
the activity resides mostly in the (S)-enantiomer. The 
(S)-naproxen is 28-times more active than the corre-
sponding (R)-enantiomer [31]. Jackson et al. claim that 
the (S) form has approximately 150-times higher activity 
than the (R) form [32]. Most of the NSAIDs are available 
at the market as racemates or single enantiomers, as 
was mentioned before, but naproxen is an exception 
because it is sold only as an (S)-enantiomer and not 
as a racemic mixture. 
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Conclusions
The phenomenon of metabolic chiral inversion 
occurs in humans and is associated with potentially 
important pharmacotherapeutic and toxicological 
consequences. Enantiomers of chiral drugs are often 
characterised by different pharmacological activity. 
Therefore, because of these effects and the consider-
able popularity of these drugs, in clinical practice admin-
istration only of (S)-enantiomers of profens (including 
dexibuprofen and dexketoprofen) should be consid-
ered. Further studies on metabolic chiral inversion of 
enantiomers in terms of pharmacovigilance are needed. 
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